Aptamer-Oligonucleotide Conjugate Development Service

Introduction How Can We Help? Deliverables Key Benefits Related Products FAQs Contact

Are you currently facing systemic toxicity, inadequate tissue penetration, or low cellular uptake in your therapeutic programs? Our Aptamer-Oligonucleotide Conjugate Development service helps you achieve cell-specific delivery of therapeutic payloads and eliminate off-target effects through chemically optimized aptamers and proprietary bioconjugation techniques.

Introduction of Aptamer-Oligonucleotide Conjugate Development

The promise of Nucleic Acid Therapeutics—such as siRNA, ASO, and miRNA—lies in their power to silence specific genes and target "undruggable" pathways. However, their full potential is hindered by poor pharmacokinetics, susceptibility to nuclease degradation, and, critically, the inability to cross biological barriers (like the Blood-Brain Barrier) or achieve cell-specific uptake.

Aptamers, often referred to as "chemical antibodies," are single-stranded DNA or RNA molecules selected to bind to specific molecular targets with high affinity and specificity. When an aptamer is covalently linked to a therapeutic oligonucleotide payload, it creates an Aptamer-Oligonucleotide Conjugate—a highly precise molecular scalpel designed for targeted delivery.

What Is Our Service?

The Creative Biolabs synthesizes, optimizes, and covalently links a targeting aptamer (the guide) to a therapeutic oligonucleotide (the payload, e.g., siRNA, ASO, or miRNA mimic/inhibitor). Application Scenarios:

Targeted Cancer Therapy: Delivering highly toxic or sensitive siRNA payloads only to specific cancer cell receptors, minimizing damage to healthy tissue.
Overcoming the Blood-Brain Barrier (BBB): Designing conjugates that target receptors known to facilitate transport across the BBB, essential for Glioblastoma (GBM) treatment.
Immunomodulation: Directing oligonucleotide payloads to specific immune cell subsets (e.g., T-cells, macrophages) to modulate the tumor microenvironment.

Why Choose Us?

For drug developers, the greatest pain point is the loss of efficacy and increased toxicity resulting from non-specific drug delivery (off-target effects and systemic exposure).

Pain Points	Benefit Created by Creative Biolabs
Poor delivery efficacy and high off-target toxicity	Creative Biolabs' conjugates achieve cell-specific internalization, dramatically reducing the required dosage, minimizing off-target side effects, and maximizing the therapeutic concentration in the target tissue. Our approach de-risks your preclinical pipeline by ensuring the therapeutic molecule reaches its intended destination.

ApDC structure diagram. (OA Literature) Fig.1 Strategies for aptamer-siRNA conjunction construction. Illustrated are various design approaches explored.¹

How Creative Biolabs' ApDC Development Service Can Assist Your Project?

Creative Biolabs' Aptamer-Oligonucleotide Conjugate Development platform provides a fully validated, ready-to-use therapeutic molecule, ensuring your project moves from concept to preclinical testing with maximum efficiency. We provide the essential upstream data required to make the downstream conjugation a success.

Workflow

Required Starting Materials
- Target ID
- Oligonucleotide Sequence
- Proposed Linker Design
Aptamer Affinity Optimization
Linker Chemistry Design
Covalent Conjugation & Purification
Structural & Quality Control (QC)
Functional Validation (In Vitro)

Uncover Your Project's Potential – Reach Out for Pricing and Availability Today!

Deliverables

Upon completion of the Aptamer-Oligonucleotide Conjugate Development service, Creative Biolabs provides a comprehensive package of materials and data:

Final Conjugate Molecule: Purified Aptamer-Oligonucleotide Conjugate.
Detailed analysis confirming the purity, molecular weight, and structural integrity of the final product.
Synthesis and Bioconjugation Protocol: A complete lab report outlining all reagents, reaction conditions, and purification steps.
Target Binding Affinity Data: Results from binding assays confirming the aptamer's activity.
In Vitro Functional Efficacy Data: Data confirming the biological activity of the payload.
Stability Assessment Report: Summary of the conjugate's stability under different storage and physiological conditions.

Key Benefits

Creative Biolabs' platform is built on two decades of experience in nucleic acid chemistry and precision bioconjugation, ensuring your project benefits from industry-leading expertise.

Precision Targeting for Low Toxicity

Our conjugates are designed to only engage receptors highly expressed on the diseased cell, offering a superior safety profile compared to systemic chemotherapy or non-targeted delivery systems.

Enhanced Stability and Half-Life

Through strategic chemical modifications to both the aptamer and the oligonucleotide, we ensure the conjugate resists nuclease degradation in vivo, significantly prolonging its circulation half-life.

Versatile Linker Chemistry

We offer a range of cleavable and non-cleavable linkers, allowing for tailored payload release kinetics optimized for your specific therapeutic application.

Proven Blood-Brain Barrier (BBB) Strategy

We focus on aptamers that target specific BBB transporters, leveraging Published Data on successful delivery systems to solve the critical tissue penetration challenge in neuro-oncology.

Uncover Your Project's Potential – Reach Out for Pricing and Availability Today!

Related Products

Aptamer Products List

Frequently Asked Questions

Q1: How does Creative Biolabs ensure the stability of the oligonucleotide payload within the conjugate?

A: We use a two-pronged strategy. First, the oligonucleotide itself is chemically stabilized before conjugation. Second, we select a linkage that minimizes steric hindrance and protects the payload from nucleases. Our final quality control includes stability testing under physiological conditions, giving you confidence in the molecule's performance.

Q2: Can your conjugates be used to target specific cell types within a heterogeneous tumor microenvironment?

A: Absolutely. This is the core strength of our service. Unlike bulk methods, aptamers are selected for incredibly high specificity against unique receptors found only on the target cell. We ensure the binding is robust and highly selective, allowing your therapeutic payload to only reach the intended pathogenic clone.

Q3: We require a payload that is only released inside the target cell. Can Creative Biolabs accommodate this?

A: Yes, our flexible Linker Chemistry Design is tailored for controlled release. We can incorporate cleavable linkers, such as those sensitive to low endosomal pH or specific intracellular enzymes. This ensures the payload is only released once the conjugate has been successfully internalized by the target cell.

Contact Us

Creative Biolabs is dedicated to accelerating your next-generation therapeutic programs through our expertise in Aptamer-Oligonucleotide Conjugate Development. We eliminate the critical risk associated with systemic delivery, providing you with high-purity, cell-specific molecules essential for clinical success in challenging indications like oncology and neuro-oncology. Contact our specialized team today for detailed technical information, tailored project scoping, and a complimentary consultation on your Aptamer-Oligonucleotide Conjugate needs.

Reference

Kruspe, Sven, and Paloma H. Giangrande. "Aptamer-siRNA chimeras: discovery, progress, and future prospects." Biomedicines 5.3 (2017): 45. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/biomedicines5030045.

For Research Use Only.